Prolonged survival without progression under crizotinib treatment

Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Zou, 2007, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms, Cancer Res, 67, 4408, 10.1158/0008-5472.CAN-06-4443 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N. Engl. J. Med., 368, 2385, 10.1056/NEJMoa1214886 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Engl. J. Med., 371, 2167, 10.1056/NEJMoa1408440 Wu, 2018, Results of PROFILE 1029, a Phase III comparison of first-line crizotinib versus chemotherapy in east Aasian patients with ALK-positive advanced non–small cell lung cancer, J. Thorac. Oncol, 13, 1539, 10.1016/j.jtho.2018.06.012 Rangachari, 2017, Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy, J. Thorac. Oncol, 12, e175, 10.1016/j.jtho.2017.06.002 Kosaka, 2019, Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: a case report, Mol. Clin. Oncol, 11, 309 Sasaki, 2010, The biology and treatment of EML4-ALK non-small cell lung cancer, Eur. J. Cancer, 46, 1773, 10.1016/j.ejca.2010.04.002 Li, 2018, Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants, Lung Cancer, 118, 128, 10.1016/j.lungcan.2018.01.026 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N. Engl. J. Med., 368, 2385, 10.1056/NEJMoa1214886 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer, N. Engl. J. Med., 363, 1693, 10.1056/NEJMoa1006448 Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol., 13, 1011, 10.1016/S1470-2045(12)70344-3 Kim, 2012, Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC), J. Clin. Oncol., 30, 10.1200/jco.2012.30.15_suppl.7533 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Engl. J. Med., 371, 2167, 10.1056/NEJMoa1408440 Engelman, 2008, Acquired resistance to tyrosine kinase inhibitors during cancer therapy, Curr. Opin. Genet. Dev, 18, 73, 10.1016/j.gde.2008.01.004 Engelman, 2008, Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer, Clin. Cancer Res., 14, 2895, 10.1158/1078-0432.CCR-07-2248 Sequist, 2011, Engelman. JA Sci. Transl. Med., 3, 75ra26 Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers, Sci. Transl. Med., 4, 120ra17, 10.1126/scitranslmed.3003316 Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N. Engl. J. Med., 363, 1734, 10.1056/NEJMoa1007478 Sasaki, 2011, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors, Cancer Res., 71, 6051, 10.1158/0008-5472.CAN-11-1340 Shaw, 2017, Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 18, 874, 10.1016/S1470-2045(17)30339-X Huber, 2020, Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial, J. Thorac. Oncol., 15, 404, 10.1016/j.jtho.2019.11.004 Novello, 2018, Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study, Ann. Oncol, 29, 1409, 10.1093/annonc/mdy121